Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06974734 · ClinicalTrials.gov registry record · Phase 1

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Malignant Melanoma, sponsored by Pfizer.

Active
Registry status
Phase 1
Development phase
9
Enrollment target
15
Study locations

NCT06974734 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Malignant Melanoma that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 9 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (97% lower). The trial reports 15 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06974734, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Malignant Melanoma, is active but no longer recruiting, sponsored by Pfizer.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
9 participants
Enrollment target
15
Study locations

Study Summary

The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies. This study is seeking participants who: * have advanced or metastatic non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, or pancreatic ductal adenocarcinoma (PDAC); * are able to provide tumor tissue samples; * have measurable disease. All participants will receive while at the clinic PF-08046037 alone as an intravenous (IV) infusion (given directly into a vein) or with sasanlimab as a subcutaneous (SQ) injection (given under the skin) once every 3 weeks. Participants will continue to take the study drug(s) until their cancer is no longer responding or if the patient cannot safely take them. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

Conditions Studied

Carcinoma, Non-Small Cell Lung Malignant Melanoma Carcinoma, Pancreatic Ductal Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Interventions

  • DRUG PF-08046037
  • DRUG sasanlimab

Study Locations (15)

Connecticut

  • Smilow Cancer Hospital - Yale New Haven Health - New Haven
  • Yale - New Haven Hospital - Yale Cancer Center - New Haven
  • Smilow Cancer Hospital Phase 1 Unit - New Haven
  • Smilow Cancer Hospital - Trumbull - Trumbull

Indiana

  • Community Health Network, Inc - Indianapolis
  • Community Health Network, Inc. - Indianapolis
  • Community Health Network, Inc. - Indianapolis
  • Community Health Network, Inc. - Indianapolis

Tennessee

  • Sarah Cannon Research Institute - Pharmacy - Nashville
  • SCRI Oncology Partners - Nashville
  • Tristar Centennial Medical Center - Nashville

Colorado

  • Presbyterian/ St. Lukes Medical Center - Denver
  • Sarah Cannon Research Institute at HealthONE - Denver

Michigan

  • START Midwest - Grand Rapids

Other

  • Pan American Center for Oncology Trials, LLC - Rio Piedras

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2025-05-06
Est. Completion 2026-04-30
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06974734

The ClinicalTrials.gov registry entry for NCT06974734 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (97% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which PF-08046037 is the first listed.

NCT06974734 reports 15 study locations spanning 6 distinct geographic areas - top geographies include Connecticut, Indiana, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06974734 about?

NCT06974734 is a clinical study titled "A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies". The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies. This study is seeking participants who: * have advanced or metastatic non-small cell lung cancer (NSCLC), head and neck s...

What is the current status of trial NCT06974734?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2025-05-06. Estimated completion is 2026-04-30.

What conditions does trial NCT06974734 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Malignant Melanoma, Carcinoma, Pancreatic Ductal, Squamous Cell Carcinoma of the Head and Neck (SCCHN).

What interventions are being tested in trial NCT06974734?

The interventions under investigation include: PF-08046037 (DRUG), sasanlimab (DRUG).

Who is sponsoring clinical trial NCT06974734?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06974734 being conducted?

This trial has 15 study locations across Colorado, Connecticut, Indiana, Michigan, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Malignant Melanoma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.